{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:15:43Z","timestamp":1784211343144,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III","award":["PI13\/00550"],"award-info":[{"award-number":["PI13\/00550"]}]},{"name":"Research in Infectious Diseases","award":["REIPI RD12\/0015"],"award-info":[{"award-number":["REIPI RD12\/0015"]}]}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ijantimicag.2018.01.014","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T16:34:53Z","timestamp":1517416493000},"page":"854-861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Evaluation of linezolid or trimethoprim\/sulfamethoxazole in combination with rifampicin as alternative oral treatments based on an in vitro pharmacodynamic model of staphylococcal biofilm"],"prefix":"10.1016","volume":"51","author":[{"given":"Cristina","family":"El Haj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Murillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Lloberas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"G\u00f3mez-Junyent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fe","family":"Tubau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Fontova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carme","family":"Cabellos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Ariza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0010","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1128\/AAC.01504-08","article-title":"Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis","volume":"53","author":"Euba","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0015","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1469-0691.2009.02761.x","article-title":"Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections","volume":"15","author":"Nguyen","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0020","first-page":"10","article-title":"Cotrimoxazole plus rifampicin in the treatment of staphylococcal osteoarticular infection","volume":"15","author":"S\u00e1nchez","year":"1997","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0025","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/jac\/dku352","article-title":"Randomized non-inferiority trial to compare trimethoprim\/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection","volume":"70","author":"Harbarth","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0030","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1086\/525536","article-title":"Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection","volume":"46","author":"Proctor","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0035","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/AAC.42.12.3086","article-title":"Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole)","volume":"42","author":"Stein","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0040","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1128\/AAC.45.11.3238-3241.2001","article-title":"Rifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patients","volume":"45","author":"Ribera","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0045","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40121-014-0032-z","article-title":"A retrospective review of the clinical experience of linezolid with or without rifampicin in prosthetic joint infections treated with debridement and implant retention","volume":"3","author":"Morata","year":"2014","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0050","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1099\/mic.0.27709-0","article-title":"Statistical assessment of a laboratory method for growing biofilms","volume":"151","author":"Goeres","year":"2005","journal-title":"Microbiology"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0055","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/bem.20529","article-title":"A biofilm growth protocol and the design of a magnetic field exposure setup to be used in the study of magnetic fields as a means of controlling bacterial biofilms","volume":"31","author":"McLeod","year":"2010","journal-title":"Bioelectromagnetics"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0060","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1128\/AAC.00455-10","article-title":"Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm","volume":"54","author":"Parra-Ruiz","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0065","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40121-014-0055-5","article-title":"Evaluation of high-dose daptomycin versus vancomycin alone or combined with clarithromycin or rifampin against Staphylococcus aureus and S. epidermidis in a novel in vitro PK\/PD model of bacterial biofilm","volume":"4","author":"Hall Snyder","year":"2015","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0070","series-title":"M07-A10: methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014tenth edition","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0075","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/nprot.2010.71","article-title":"Microtiter susceptibility testing of microbes growing on peg lids: a miniaturized biofilm model for high-throughput screening","volume":"5","author":"Harrison","year":"2010","journal-title":"Nat Protoc"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0080","series-title":"Kucers' the use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs","author":"Grayson","year":"2010"},{"issue":"Suppl.A","key":"10.1016\/j.ijantimicag.2018.01.014_bib0085","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jac\/15.suppl_A.125","article-title":"In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives","volume":"15","author":"Blaser","year":"1985","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0090","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1093\/jac\/dku151","article-title":"Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model","volume":"69","author":"Lora-Tamayo","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0095","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.mimet.2006.10.018","article-title":"Enhanced visualization of microbial biofilms by staining and environmental scanning electron microscopy","volume":"68","author":"Priester","year":"2007","journal-title":"J Microbiol Methods"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jinf.2011.07.001","article-title":"Efficacy of tigecycline alone and with rifampin in foreign-body infection by methicillin-resistant Staphylococcus aureus","volume":"63","author":"Garrig\u00f3s","year":"2011","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0105","article-title":"Drawbacks of the use of cotrimoxazole in foreign-body infections","author":"El Haj","year":"2017","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0110","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/clinids\/14.6.1251","article-title":"Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations","volume":"14","author":"Widmer","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0115","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/cir402","article-title":"Outcome and predictors of treatment failure in total hip\/knee prosthetic joint infections due to Staphylococcus aureus","volume":"53","author":"Senneville","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0120","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/cid\/cis746","article-title":"A large multicenter study of methicillin-susceptible and methicillin-resistant staphylococcus aureus prosthetic joint infections managed with implant retention","volume":"56","author":"Lora-Tamayo","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0125","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMra040181","article-title":"Prosthetic-joint infections","volume":"351","author":"Zimmerli","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0130","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eimc.2016.08.012","article-title":"Executive summary of management of prosthetic joint infections. Clinical practice guidelines by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)","volume":"35","author":"Ariza","year":"2017","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0135","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1128\/AAC.00523-06","article-title":"Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus","volume":"50","author":"Murillo","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0140","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1128\/AAC.37.6.1334","article-title":"Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome","volume":"37","author":"Walsh","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0145","doi-asserted-by":"crossref","first-page":"h2219","DOI":"10.1136\/bmj.h2219","article-title":"Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial","volume":"350","author":"Paul","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0150","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1128\/AAC.39.4.953","article-title":"Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis","volume":"39","author":"de G\u00f3rgolas","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0155","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1128\/AAC.17.4.591","article-title":"Treatment of experimental staphylococcal osteomyelitis with rifampin and trimethoprim, alone and in combination","volume":"17","author":"Norden","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0160","first-page":"385","article-title":"[Bone diffusion of trimethoprim and sulfamethoxazole high pressure liquid chromatography (HPLC) (author's transl)]","volume":"30","author":"Saux","year":"1982","journal-title":"Pathol Biol (Paris)"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0165","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1128\/AAC.00775-08","article-title":"Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection","volume":"53","author":"Baldoni","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0170","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1128\/AAC.00352-11","article-title":"Linezolid plus rifampin as a salvage therapy in prosthetic joint infections treated without removing the implant","volume":"55","author":"G\u00f3mez","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0175","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/jac\/dkv481","article-title":"Importance of selection and duration of antibiotic regimen in prosthetic joint infections treated with debridement and implant retention","volume":"71","author":"Tornero","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0180","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1592\/phco.27.3.476","article-title":"Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin","volume":"27","author":"Gebhart","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0185","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1128\/AAC.01081-09","article-title":"Continuous clindamycin infusion, an innovative approach to treating bone and joint infections","volume":"54","author":"Zeller","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0190","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/bcp.13178","article-title":"Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid","volume":"83","author":"Marsot","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0195","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3109\/00365548.2012.663931","article-title":"Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections","volume":"44","author":"Hoyo","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.01.014_bib0200","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/jac\/dkq281","article-title":"Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?","volume":"65","author":"Legout","year":"2010","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918300177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918300177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T21:40:28Z","timestamp":1719783628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918300177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0924857918300177"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.01.014","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of linezolid or trimethoprim\/sulfamethoxazole in combination with rifampicin as alternative oral treatments based on an in vitro pharmacodynamic model of staphylococcal biofilm","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}